Abstract
Tolfenamic acid (TA) is a non-steroidal anti-inflammatory drug associated with anti-tumorigenic and pro-apoptotic properties in animal and in vitro models of cancer. However, the underlying cellular mechanisms by which TA exerts its effects are only partially understood. Activating transcription factor 3 (ATF3) is a member of the ATF/CREB subfamily of the basic region-leucine zipper family and has been known as a tumor suppressor in human colorectal cancer cells. The present study was performed to observe whether ATF3 mediates TA-induced apoptosis and to elucidate the molecular mechanism of ATF3 transcription induced by TA. TA treatment and ectopic expression of ATF3 increased apoptosis, whereas knockdown of ATF3 resulted in significant repression of TA-activated apoptosis. The TA treatment also induced ATF3 promoter activity. Internal deletion and point mutation of the predicted ATF/C/EBP binding site in ATF3 promoter abolished luciferase activation by TA. Overexpression of ATF2 resulted in significant increase in ATF3 promoter activity, and electrophoretic mobility shift assay identified this region as a core sequence to which ATF2 binds. TA treatment resulted in an increase in ATF2 phosphorylation, which was followed by a subsequent increase in ATF3 transcription. Knock down of ATF2 abolished TA-induced ATF3 expression. We further provide evidence that TA leads to increases in phospho-p38 MAPK, JNK and ERK levels. Inhibition of these pathways using selective inhibitors and dominant negative constructs ameliorated TA-induced ATF3 expression and promoter activities. The current study shows that TA stimulates ATF3 expression and subsequently induces apoptosis. These pathways are mediated through phosphorylation of ATF2, which is mediated by p38 MAPK-, JNK- and ERK-dependent pathways.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Abdelrahim M, Baker CH, Abbruzzese JL, Safe S . (2006). Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation. J Natl Cancer Inst 98: 855–868.
Abdelrahim MB, Baker CH, Abbruzzese JL, Sheikh-Hamad D, Liu S, Cho SD et al. (2007). Regulation of vascular endothelial growth factor receptor-1 expression by specificity proteins 1, 3, and 4 in pancreatic cancer cells. Cancer Res 67: 3286–3294.
Allan AL, Albanese C, Pestell RG, LaMarre J . (2001). Activating transcription factor 3 induces DNA synthesis and expression of cyclin D1 in hepatocytes. J Biol Chem 276: 27272–27280.
Baek SJ, Kim JS, Jackson FR, Eling TE, McEntee MF, Lee SH . (2004). Epicatechin gallate-induced expression of NAG-1 is associated with growth inhibition and apoptosis in colon cancer cells. Carcinogenesis 25: 2425–2432.
Bhoumik A, Fichtman B, Derossi C, Breitwieser W, Kluger HM, Davis S et al. (2008). Suppressor role of activating transcription factor 2 (ATF2) in skin cancer. Proc Natl Acad Sci USA 105: 1674–1679.
Bhoumik A, Ronai Z . (2008). ATF2: a transcription factor that elicits oncogenic or tumor suppressor activities. Cell Cycle 7: 2341–2345.
Bottone Jr FG., Martinez JM, Alston-Mills B, Eling TE . (2004). Gene modulation by Cox-1 and Cox-2 specific inhibitors in human colorectal carcinoma cancer cells. Carcinogenesis 25: 349–357.
Bottone Jr FG, Moon Y, Kim JS, Alston-Mills B, Ishibashi M, Eling TE . (2005). The anti-invasive activity of cyclooxygenase inhibitors is regulated by the transcription factor ATF3 (activating transcription factor 3). Mol Cancer Ther 4: 693–703.
Brown SL, Sekhar KR, Rachakonda G, Sasi S, Freeman ML . (2008). Activating transcription factor 3 is a novel repressor of the nuclear factor erythroid-derived 2-related factor 2 (Nrf2)-regulated stress pathway. Cancer Res 68: 364–368.
Cai Y, Zhang C, Nawa T, Aso T, Tanaka M, Oshiro S et al. (2000). Homocysteine-responsive ATF3 gene expression in human vascular endothelial cells: activation of c-Jun NH(2)-terminal kinase and promoter response element. Blood 96: 2140–2148.
Chen HH, Wang DL . (2004). Nitric oxide inhibits matrix metalloproteinase-2 expression via the induction of activating transcription factor 3 in endothelial cells. Mol Pharmacol 65: 1130–1140.
Cho KN, Sukhthankar M, Lee SH, Yoon JH, Baek SJ . (2007). Green tea catechin (-)-epicatechin gallate induces tumour suppressor protein ATF3 via EGR-1 activation. Eur J Cancer 43: 2404–2412.
Deng X, Liu H, Huang J, Cheng L, Keller ET, Parsons SJ et al. (2008). Ionizing radiation induces prostate cancer neuroendocrine differentiation through interplay of CREB and ATF2: implications for disease progression. Cancer Res 68: 9663–9670.
Fan F, Jin S, Amundson SA, Tong T, Fan W, Zhao H et al. (2002). ATF3 induction following DNA damage is regulated by distinct signaling pathways and over-expression of ATF3 protein suppresses cells growth. Oncogene 21: 7488–7496.
Fuchs SY, Tappin I, Ronai Z . (2000). Stability of the ATF2 transcription factor is regulated by phosphorylation and dephosphorylation. J Biol Chem 275: 12560–12564.
Gupta RA, Dubois RN . (2001). Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 1: 11–21.
Hai T, Hartman MG . (2001). The molecular biology and nomenclature of the activating transcription factor/cAMP responsive element binding family of transcription factors: activating transcription factor proteins and homeostasis. Gene 273: 1–11.
Hai TW, Liu F, Allegretto EA, Karin M, Green MR . (1988). A family of immunologically related transcription factors that includes multiple forms of ATF and AP-1. Genes Dev 2: 1216–1226.
Hansen PE . (1994). Tolfenamic acid in acute and prophylactic treatment of migraine: a review. Pharmacol Toxicol 75 (Suppl 2): 81–92.
Hao F, Tan M, Xu X, Han J, Miller DD, Tigyi G et al. (2007). Lysophosphatidic acid induces prostate cancer PC3 cell migration via activation of LPA(1), p42 and p38alpha. Biochim Biophys Acta 1771: 883–892.
Huang X, Li X, Guo B . (2008). KLF6 induces apoptosis in prostate cancer cells through up-regulation of ATF3. J Biol Chem 283: 29795–29801.
Iyer VR, Eisen MB, Ross DT, Schuler G, Moore T, Lee JC et al. (1999). The transcriptional program in the response of human fibroblasts to serum. Science 283: 83–87.
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ . (2009). Cancer statistics, 2009. CA Cancer J Clin 59: 225–249.
Kashiwakura Y, Ochiai K, Watanabe M, Abarzua F, Sakaguchi M, Takaoka M et al. (2008). Down-regulation of inhibition of differentiation-1 via activation of activating transcription factor 3 and Smad regulates REIC/Dickkopf-3-induced apoptosis. Cancer Res 68: 8333–8341.
Lee SH, Bahn JH, Choi CK, Whitlock NC, English AE, Safe S et al. (2008). ESE-1/EGR-1 pathway plays a role in tolfenamic acid-induced apoptosis in colorectal cancer cells. Mol Cancer Ther 7: 3739–3750.
Lee SH, Kim JS, Yamaguchi K, Eling TE, Baek SJ . (2005). Indole-3-carbinol and 3,3′-diindolylmethane induce expression of NAG-1 in a p53-independent manner. Biochem Biophys Res Commun 328: 63–69.
Lee SH, Yamaguchi K, Kim JS, Eling TE, Safe S, Park Y et al. (2006). Conjugated linoleic acid stimulates an anti-tumorigenic protein NAG-1 in an isomer specific manner. Carcinogenesis 27: 972–981.
Lu D, Wolfgang CD, Hai T . (2006). Activating transcription factor 3, a stress-inducible gene, suppresses Ras-stimulated tumorigenesis. J Biol Chem 281: 10473–10481.
Maekawa T, Sakura H, Kanei-Ishii C, Sudo T, Yoshimura T, Fujisawa J et al. (1989). Leucine zipper structure of the protein CRE-BP1 binding to the cyclic AMP response element in brain. EMBO J 8: 2023–2028.
Maekawa T, Sano Y, Shinagawa T, Rahman Z, Sakuma T, Nomura S et al. (2008). ATF-2 controls transcription of Maspin and GADD45 alpha genes independently from p53 to suppress mammary tumors. Oncogene 27: 1045–1054.
Maekawa T, Shinagawa T, Sano Y, Sakuma T, Nomura S, Nagasaki K et al. (2007). Reduced levels of ATF-2 predispose mice to mammary tumors. Mol Cell Biol 27: 1730–1744.
Miyazaki K, Inoue S, Yamada K, Watanabe M, Liu Q, Watanabe T et al. (2009). Differential usage of alternate promoters of the human stress response gene ATF3 in stress response and cancer cells. Nucleic Acids Res 37: 1438–1451.
Oh YK, Lee HJ, Jeong MH, Rhee M, Mo JW, Song EH et al. (2008). Role of activating transcription factor 3 on TAp73 stability and apoptosis in paclitaxel-treated cervical cancer cells. Mol Cancer Res 6: 1232–1249.
Ouwens DM, de Ruiter ND, van der Zon GC, Carter AP, Schouten J, van der Burgt C et al. (2002). Growth factors can activate ATF2 via a two-step mechanism: phosphorylation of Thr71 through the Ras-MEK-ERK pathway and of Thr69 through RalGDS-Src-p38. EMBO J 21: 3782–3793.
Parkin DM, Bray F, Ferlay J, Pisani P . (2005). Global cancer statistics, 2002. CA Cancer J Clin 55: 74–108.
Piyanuch R, Sukhthankar M, Wandee G, Baek SJ . (2007). Berberine, a natural isoquinoline alkaloid, induces NAG-1 and ATF3 expression in human colorectal cancer cells. Cancer Lett 258: 230–240.
Tamura K, Hua B, Adachi S, Guney I, Kawauchi J, Morioka M et al. (2005). Stress response gene ATF3 is a target of c-myc in serum-induced cell proliferation. Embo J 24: 2590–2601.
Whitmore MM, Iparraguirre A, Kubelka L, Weninger W, Hai T, Williams BR . (2007). Negative regulation of TLR-signaling pathways by activating transcription factor-3. J Immunol 179: 3622–3630.
Wolfgang CD, Liang G, Okamoto Y, Allen AE, Hai T . (2000). Transcriptional autorepression of the stress-inducible gene ATF3. J Biol Chem 275: 16865–16870.
Woo IS, Kohno T, Inoue K, Ishii S, Yokota J . (2002). Infrequent mutations of the activating transcription factor-2 gene in human lung cancer, neuroblastoma and breast cancer. Int J Oncol 20: 527–531.
Xue L, Firestone GL, Bjeldanes LF . (2005). DIM stimulates IFNgamma gene expression in human breast cancer cells via the specific activation of JNK and p38 pathways. Oncogene 24: 2343–2353.
Yamaguchi K, Lee SH, Kim JS, Wimalasena J, Kitajima S, Baek SJ . (2006). Activating transcription factor 3 and early growth response 1 are the novel targets of LY294002 in a phosphatidylinositol 3-kinase-independent pathway. Cancer Res 66: 2376–2384.
Yan C, Boyd DD . (2006). ATF3 regulates the stability of p53: a link to cancer. Cell Cycle 5: 926–929.
Yan C, Lu D, Hai T, Boyd DD . (2005). Activating transcription factor 3, a stress sensor, activates p53 by blocking its ubiquitination. Embo J 24: 2425–2435.
Yin X, Dewille JW, Hai T . (2008). A potential dichotomous role of ATF3, an adaptive-response gene, in cancer development. Oncogene 27: 2118–2127.
Acknowledgements
We thank Dr T Hai (Ohio State University, Columbus, OH, USA) and Dr S Kitajima (Tokyo Medical and Dental University, Tokyo, Japan) for providing the pCG-ATF3 construct and ATF3 promoter, respectively. We thank Dr Philip Cohen (University of Dundee, Scotland, UK) and Dr Joo-Heon Yoon (Yonsei University, Seoul, Korea) for providing pEBG2T-GST-ATF2-6His- and CREB-expression vector, respectively. We thank Dr Melanie Cobb (University of Texas Southwestern Medical Center, Dallas, TX, USA) for providing wild type and dominant negative ERK2-expression vector. We also thank Misty Bailey for her critical reading of the paper. This work was supported by Grants from the American Cancer Society (CNE-111611), National Institutes of Health (R01CA108975) and the University of Tennessee, Center of Excellence in Livestock Diseases and Human Health to SJB.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Lee, SH., Bahn, J., Whitlock, N. et al. Activating transcription factor 2 (ATF2) controls tolfenamic acid-induced ATF3 expression via MAP kinase pathways. Oncogene 29, 5182–5192 (2010). https://doi.org/10.1038/onc.2010.251
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2010.251
Keywords
This article is cited by
-
The two-faced role of ATF2 on cisplatin response in gastric cancer depends on p53 context
Cell & Bioscience (2022)
-
The role of Nrf2 and ATF2 in resistance to platinum-based chemotherapy
Cancer Chemotherapy and Pharmacology (2017)
-
Anti-cancer activity of Ginger (Zingiber officinale) leaf through the expression of activating transcription factor 3 in human colorectal cancer cells
BMC Complementary and Alternative Medicine (2014)
-
The induction of activating transcription factor 3 (ATF3) contributes to anti-cancer activity of Abeliophyllum distichum Nakai in human colorectal cancer cells
BMC Complementary and Alternative Medicine (2014)
-
Combination of MEK and SRC inhibition suppresses melanoma cell growth and invasion
Oncogene (2013)